A blood test being developed by Roche and Eli Lilly that could help diagnose patients with Alzheimer’s disease more quickly has been awarded breakthrough status by the FDA, which could help it to reach the market more quickly.
The pTau217 plasma biomarker test, which runs on Roche’s widely-used Elecsys analysers, is intended to look for the presence or absence of amyloid pathology in individuals with suspected Alzheimer’s.
